Van ECK Associates Corp Raises Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Van ECK Associates Corp grew its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,875,387 shares of the company’s stock after buying an additional 208,673 shares during the quarter. Van ECK Associates Corp’s holdings in Teva Pharmaceutical Industries were worth $34,526,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Sequoia Financial Advisors LLC raised its holdings in shares of Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after buying an additional 805 shares during the period. Edmond DE Rothschild Holding S.A. lifted its holdings in shares of Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after purchasing an additional 947 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after acquiring an additional 1,094 shares during the period. Oppenheimer & Co. Inc. increased its stake in Teva Pharmaceutical Industries by 9.6% in the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after purchasing an additional 1,180 shares during the period. Finally, QRG Capital Management Inc. raised its stake in Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after acquiring an additional 1,191 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Up 1.0 %

TEVA stock opened at $18.64 on Tuesday. Teva Pharmaceutical Industries Limited has a 12 month low of $8.55 and a 12 month high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The company’s 50 day simple moving average is $18.03 and its 200-day simple moving average is $17.02. The firm has a market capitalization of $21.12 billion, a PE ratio of -47.79, a P/E/G ratio of 1.33 and a beta of 0.87.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.